China’s Life Science sector is growing at remarkable speed. Driven by innovation, investment, and a strong focus on Healthcare transformation. In this keynote, Harry Li will explore what makes China such a compelling yet complex market for Nordic Life Science companies.

With concrete examples and actionable advice, this session will help Nordic companies grasp the real opportunities and challenges of entering or expanding in China’s dynamic Life Science landscape.

Hear directly from leading specialist investors in the life science space as they reveal what truly makes a company stand out. This panel will delve into the critical drivers of investment decisions – from breakthrough science and scalable business models to strong leadership teams and clear market opportunities. Whether you are building an early-stage startup or advancing a growing biotech, you will gain actionable insights on how to position your company for funding success. As an investor, your may gain some tips and tricks!

Ester Sklarsky, Principal, Sound Bioventure
Søren Lemonius, Managing General Partner, Sunstone Life Science Ventures
Shamim Dadvar, Associate, HealthCap
Markus Dietrich, Senior Investment Associate, Hadean Ventures
Bita Sehat, Partner, Trill Impact

Bringing medtech innovations to market requires more than breakthrough technology. This panel explores strategies for navigating the early stages of commercialization, from regulatory and market entry hurdles to shaping launch plans. Hear how leading experts emphasize flexibility in strategy and execution to maximize adoption and long-term success.

Anna Gisselsson, Investment Manager, Almi Invest
Emil Billbäck, Strategic Advisor, Bonesupport
Karin Leire, Investment Director, Segulah Medical
Philip Siberg, CEO, Senzime
Andreas Forsvall, CEO, Xaga Surgical

A panel discussion exploring how AI is transforming drug development and healthcare. Hear from leaders across cutting-edge biotechs with AI-driven platforms, scientific innovators and principal investigators. Together, they’ll discuss breakthroughs, challenges, and the future of AI in accelerating discovery, improving patient outcomes, and reshaping the healthcare landscape.

Lisa Rydén, Professor of Surgery, Lund University
Madeleine Gustavsson, CEO, Navari Surgical
Albin Boman, CEO, Anyo Labs
Alex Zhavoronkov, CEO, Insilico Medicine
Johan Strömquist, President & Chief Innovation Officer, SSI Strategy LLC

Discover what it takes to be “deal ready” in today’s increasingly competitive life science landscape. This panel brings together pharma executives, biotech innovators, and investors to share insights on building successful partnerships. From aligning science with strategy to navigating valuation, due diligence, and collaboration models, the discussion will unpack the essential playbook for securing pharma deals and accelerating innovation.

Anu Balendran, Head of Transactions in BD&L, Cardio Renal Metabolism, Novartis
Bo Skaaning Jensen, Sr. Director, Alliance Management, Novo Nordisk
Maarit Merla, Managing Director, Finnish Drug Discovery Centre
Jonathan Sjögren, Search & Evalutation, Respiratory & Immunology, AstraZeneca
Jesper Lykkesfeldt, Lykkesfeldt

This dynamic panel discussion will unpack the trends in women’s health – where savvy investors and bold innovators are pouring resources into game-changing solutions. We will dive into the persistent hurdles of securing funding and scaling commercialization, while examining how the volatile U.S. political landscape is reshaping priorities and possibilities for the sector.

We will also delve into how the Nordic region is leading the charge, pioneering cutting-edge innovations that are redefining women’s health and paving the way for a more equitable future.

Tara Heitner, Heitner Biopharm Consultation
Diana Torgersen, Head of Innovation Ecosystem Integration, Organon
Malin Frithiofsson, CEO, Daya Ventures